These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25388738)

  • 1. Multiple sclerosis: managing a complex neurological disease.
    Embrey N
    Nurs Stand; 2014 Nov; 29(11):49-58. PubMed ID: 25388738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis in childhood: understanding and caring for children with an "adult" disease.
    Boyd JR; MacMillan LJ
    Axone; 2000 Dec; 22(2):15-21. PubMed ID: 11901486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the community nurse in care provision for people with multiple sclerosis.
    Strickland K; Baguley F
    Br J Community Nurs; 2015 Jan; 20(1):6-10. PubMed ID: 25559023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term management of patients with multiple sclerosis.
    Weightman C
    Br J Community Nurs; 2006 Jul; 11(7):303-7. PubMed ID: 16926711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod for multiple sclerosis: a review for the specialist nurse.
    Harrison K
    Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community management and pioneering treatments in MS.
    Mendes A
    Br J Community Nurs; 2016 Feb; 21(2):107. PubMed ID: 26844607
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging oral therapies for multiple sclerosis.
    Miller CE; Umhauer MA
    J Neurosci Nurs; 2011 Feb; 43(1):3-14; quiz 15-6. PubMed ID: 21338040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: managing patients in primary care.
    Maloni HW
    Nurse Pract; 2013 Apr; 38(4):24-35; quiz 35-6. PubMed ID: 23454903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benchmarking best practice in relapse management of multiple sclerosis.
    Embrey N; Lowndes C
    Nurs Stand; 2003 Feb 12-18; 17(22):38-42. PubMed ID: 12619406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Care of people with multiple sclerosis in the community setting.
    Barnes F
    Br J Community Nurs; 2007 Dec; 12(12):552, 554-7. PubMed ID: 18361167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a learning needs assessment scale: a continuing professional education tool for multiple sclerosis specialist nurses.
    While A; Ullman R; Forbes A
    J Clin Nurs; 2007 Jun; 16(6):1099-108. PubMed ID: 17518884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: understanding a complex neurological condition.
    MacLean R
    Nurs Stand; 2010 Mar 17-23; 24(28):50-6; quiz 58. PubMed ID: 20391676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
    Kennedy P
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S3-13. PubMed ID: 24217189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.
    Veugelers PJ; Fisk JD; Brown MG; Stadnyk K; Sketris IS; Murray TJ; Bhan V
    Mult Scler; 2009 Nov; 15(11):1286-94. PubMed ID: 19965558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nurse-led, patient-centred mitoxantrone service in neurology.
    Harrison E; Porter B
    Br J Nurs; 2004 Sep 23-Oct 13; 13(17):1021-3. PubMed ID: 15549012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
    Eckstein C; Bhatti MT
    Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1835-46. PubMed ID: 24993135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.